Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTCD)
is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technologies. The company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Latest Press ReleasesSeptember 5, 2014
Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources September 2, 2014
Distinguished Scientists Join Advanced Cell Technology’s New Scientific Advisory Board August 27, 2014
Advanced Cell Technology Announces 1:100 Reverse Stock Split